PharmaShots | Incisive News in 3 Shots

Subscribe Now

Metastatic NSCLC

Exelixis Reports Completion of Patient Enrollment in P-III CONTACT-01 Trial of Cabometyx (cabozantinib) + Tecentriq (atezolizumab) for Metastatic NSCLC

Exelixis Reports Completion of Patient Enrollment in P-III CONTACT-01 Trial of Cabometyx (cabozantinib) + Tecentriq (atezolizumab)...

November 10, 2021

Merck KGaA Expand its Collaboration with NKMax to Evaluate the Combination of SNK01 + Erbitux (cetuximab) for Metastatic NSCLC

Merck KGaA Expand its Collaboration with NKMax to Evaluate the Combination of SNK01 + Erbitux (cetuximab) for Metastatic NSCLC

April 14, 2021

Merck KGaA's Tepmetko (tepotinib) Receives the US FDA's Approval for Patients with Metastatic NSCLC with METex14 Skipping Alterations

Merck KGaA's Tepmetko (tepotinib) Receives the US FDA's Approval for Patients with Metastatic NSCLC with METex14 Skipping Alterati...

February 4, 2021

Merck KGaA's Tepotinib Receives FDA's Breakthrough Therapy Designation for Metastatic NSCLC with METex14 Skipping Alterations

Merck KGaA's Tepotinib Receives FDA's Breakthrough Therapy Designation for Metastatic NSCLC with METex14 Skipping Alterations

September 11, 2019

Eisai Reports Results of Lenvima (Lenvatinib) + Keytruda (pembrolizumab) to Treat Metastatic NSCLC Metastatic Melanoma and Metastatic Urothelial Carcinoma

Eisai Reports Results of Lenvima (Lenvatinib) + Keytruda (pembrolizumab) to Treat Metastatic NSCLC Metastatic Melanoma and Metasta...

November 12, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us